Australia markets closed

Genetic Technologies Limited (GNTLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00200.0000 (0.00%)
At close: 08:55AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.0020
Open0.0020
BidN/A x N/A
AskN/A x N/A
Day's range0.0020 - 0.0020
52-week range0.0020 - 0.0150
Volume1,000
Avg. volume0
Market cap26.272M
Beta (5Y monthly)1.08
PE ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Genetic Technologies Reports Q2 FY22 Cash Flow Results

    Q2 momentum sets the stage for a strong FY22MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter ended December 31, 2021. Highlights: Solid cash balance of A$13.5 million and increased customer receipts of A$1.8 million further extending runway for growth‘One company two brands’ approach leverages EasyDNA

  • GlobeNewswire

    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a global leader in genomics-based tests in health, wellness and serious disease provides the following business update:

    Cash Receipts (A$'000) Cash Receipts (A$'000) Forecast 2QFY221 cash receipts +112% versus the prior quarter (1QFY22) to A$1.8 million following the completed integration of EasyDNA in the quarterMulti-Test technical validation complete and submitted to NATA2 and CMS3 for final regulatory approval ahead of the commercial releaseUS patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation study completed in independent cohort confirming test performance and ut

  • GlobeNewswire

    GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium

    MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium. New geneType Breast Cancer Test showed improved discrimination and calibration over traditional clinical modelsStudy included over